Chugai launches Phesgo in Japan

24 November 2023

Japan’s Chugai Pharmaceuticals (TYO: 4519) revealed that it has now launched its Phesgo, a subcutaneous injection combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase on the domestic market.

Phesgo is an antineoplastic agent/anti-HER2 humanized monoclonal antibody for the treatment of HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemotherapy and is not amenable to curative resection, said Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX).

Phesgo had been approved by the Ministry of Health, Labor and Welfare (MHLW) on September 25, 2023, but has only now been added to the national health insurance (NHI) reimbursement price list.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK